<DOC>
	<DOCNO>NCT00562510</DOCNO>
	<brief_summary>This Phase 3 , randomize , double blind , placebo-controlled study design compare safety , tolerability , antiviral activity immunological effect raltegravir add previously stable HAART regimen treatment HIV-1 infected subject undetectable viraemia low CD4 recovery . HYPOTHESIS : Adding raltegravir stable HAART patient undetectable plasma viral load low CD4 recovery result viral suppression therefore high CD4 recovery .</brief_summary>
	<brief_title>Raltegravir Added Stable HAART HIV-1 Infected Subjects With Viral Suppression Low CD4 Recovery</brief_title>
	<detailed_description>Although HAART reduce morbidity mortality HIV-1 infection , patient experience discordant response characterize HIV-1 RNA plasma level limit detection low CD4 T-cell recovery ( immunologic discordant responder ) . At present , recommendation clinical management patient discordant response antiretroviral therapy largely base observational , uncontrolled data . The effect CD4 count add raltegravir already undetectable patient yet evaluate . The primary purpose study assess ability HIV-1 integrase inhibitor , raltegravir , add stable HAART , increase CD4 count patient undetectable plasma viral load low CD4 recovery .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Documented HIV1 infection . Subject voluntarily sign date informed consent form . Documented sustained HIV RNA &lt; 50 copies/ml ( two consecutive pVL &lt; 50 copies/ml , first VL &gt; 12 month screen date ) without documentation HIV RNA &gt; 50 copies/ml least 12 month previous stable HAART ( PS_HAART ) . HIV RNA &lt; 50 copies/ml screening . Subject currently receive antiretroviral regimen change least 12 month . CD4 count &lt; 200 cells/ mm3 AND CD4 increase &lt; 100 cells/ mm3 last 12 month . Subject 's vital sign , physical examination laboratory result exhibit evidence acute illness . Negative serum urine pregnancy test willing use acceptable mean contraception . Patient receive tenofovir DF AND didanosine component background antiretroviral therapy . Patient current ( active ) diagnosis acute hepatitis due cause OR chronic hepatitis B and/or C WITH aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal ( ULN ) AND/OR likely require treatment next year . Subject significant history cardiac , renal , neurologic , psychiatric , oncologic , metabolic , hepatic disease condition , investigator opinion , could compromise subject 's safety adherence trial protocol . Subject currently active AIDS defining illness ( category C condition accord CDC Classification System HIV infection 1993 ) within 30 day screen . Subjects stable maintenance therapy opportunistic infection may enrol . Life expectancy &lt; 1 year accord judgment investigator . Screening laboratory analysis show follow abnormal laboratory result : Hemoglobin &lt; 8.0 g/dL Absolute neutrophil count &lt; 750 cells/ÂµL Platelet count &lt; 50,000 mm3 Use investigational agent within 30 day prior screen . Previous use integrase inhibitor . Use immunosuppressive drug , cytokine inhibitor cytokine last year . Continuous use systemic corticoid month last year use last 3 month . Subject ongoing history substance abuse psychiatric illness . Subject pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>HIV-1 infection</keyword>
	<keyword>raltegravir</keyword>
	<keyword>immune discordance</keyword>
	<keyword>treatment experience</keyword>
</DOC>